RxDoctor Payments Data
★ My doctorsLook up a doctor →

Richard Handler

Nephrology · Vero Beach, FLNPI 1932158235

Payments from drug & device makers

$2,794in general payments, 2019–2025

Across 123 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$496
  • Amgen$360
  • Otsuka America Pharmaceutical, Inc.$210
  • Bayer$210
  • Vifor Pharma, Inc.$146
  • Novartis$143
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,64995%
  • Education$1445%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca23$496
Amgen(2 entities)18$360
Otsuka America Pharmaceutical, Inc.9$210
Bayer11$210
Vifor Pharma, Inc.7$146
Novartis2$143
Medtronic1$125
Novo Nordisk7$119
OPKO Pharmaceuticals, LLC6$115
Alnylam Pharmaceuticals Inc.4$99
Resmed Corp1$76
Mallinckrodt Enterprises LLC3$72
Lilly USA, LLC4$72
Calliditas Therapeutics US Inc.3$70
ANI Pharmaceuticals, Inc.4$64
Fresenius USA Marketing, Inc.3$57
Amicus Therapeutics, Inc.2$46
Baxter Healthcare1$44
Mallinckrodt Hospital Products Inc.2$43
GSK2$39
Sanofi2$38
Johnson & Johnson2$30
Akebia Therapeutics Inc2$29
Daiichi Sankyo Inc.1$25
Shire North American Group Inc1$23
Aurinia Pharma U.S., Inc.1$22
Genentech USA, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,794 in reported general payments places this provider in the 60th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida →

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$22,413
FarxigaDapagliflozin Propanediol30$20,090
JardianceEmpagliflozin14$17,545
KerendiaFinerenone11$15,667
Valsartan25$756
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide15$398
Allopurinol25$325
Losartan Potassium21$258
Omeprazole17$246
Levothyroxine Sodium20$222
Atorvastatin Calcium27$209
Glimepiride18$148
Indapamide12$147
Amlodipine Besylate14$111
Glipizide11$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$119$22,41315 claims
AstraZenecaFarxiga$496$20,09030 claims
BayerKerendia$210$15,66711 claims
ANI Pharmaceuticals, Inc.Valsartan$64$75625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 756 nephrology providers in Florida.

Other nephrology in Vero Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →